Survodutide is an experimental peptide that works as a dual glucagon/GLP-1 receptor agonist. Unlike other dual GLP-1/glucagon dual agonists, it is a glucagon analog rather than an analog of oxyntomodulin. From Wikipedia
The FDA designation expedites the development of survodutide, a promising dual receptor agonist, for treating non-cirrhotic MASH with moderate to advanced fibrosis.
